UK invests in Oxford bioscience site
January 31, 2014Research and Development, Sales and Marketing Milton Park, Oxford, UK, bioscience, government
The government is putting £7 million into Milton Park, near Oxford, to boost the building of a new laboratory and …
Nintendo plans new healthcare venture
January 31, 2014Medical Communications, Sales and Marketing digital, games, healthcare, nintendo, wii
Console giant Nintendo has confirmed that it is about to set up a new healthcare business separate from its entertainment …
Metamark names new chief commercial officer
January 31, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cornelius, metamark
US Biotech firm Metamark Genetics has named the former general manager of HealthTronics Laboratory Solutions Cornelius Merlini, as its senior …
Lilly to go ‘on offense’
January 31, 2014Sales and Marketing Alimta, Lechleiter, cymbalta, lilly, q4, zyprexa
The loss of patent on antidepressant Cymbalta in the US last December was largely responsible for Eli Lilly & Co’s …
Oncology drives Roche profits
January 30, 2014Sales and Marketing Actemra, Perjeta, Roche, Swiss, q4
Sales at Roche’s pharma division rose 7% year-on-year in 2013, driven largely by strong performances from its oncology portfolio. Group …
Stem cell breakthrough heralded by scientists
January 30, 2014Research and Development, Sales and Marketing BBC, regenerative medicine, stap, stem cell
Researchers have discovered a simple method of producing mice stem cells that could mark a new era of regenerative medicine. …
Novo Nordisk appoints chief medical officer
January 30, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, todd hobbs
Dr Todd Hobbs has been appointed chief medical officer (CMO) for Novo Nordisk in North America. In this role …
Sales rise for Novartis
January 30, 2014Sales and Marketing Gleevec, Glivec, Novartis, gilenya, q4, sales
Multiple sclerosis drug Gilenya, with sales rising 62% year-on-year to $1.9 billion, was one of the stars of last year …
GSK halts chickenpox vaccines over quality concerns
January 29, 2014Manufacturing and Production, Sales and Marketing Boostrix-Polio, GSK, Varilrix, chickenpox, vaccines
GlaxoSmithKline has suspended worldwide distribution of two chickenpox vaccines after production standards were not met at one of its facilities …
Profits drop for Pfizer
January 29, 2014Sales and Marketing Enbrel, Lipitor, Pfizer, Spiriva, Zoetis, q4
Pfizer’s turnover fell to $54.6 billion in 2013, a 6% drop year-on-year from $54.7 billion in 2012, but the group …
High-dose Copaxone the right medicine for Teva
January 29, 2014Research and Development, Sales and Marketing Biogen, Copaxone, FDA, MS, Mylan, Teva
The FDA has approved a high-dose version of Teva’s multiple sclerosis drug Copaxone which will help the firm offset approaching …
Merck KGaA head jumping ship to Lanxess
January 29, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, Merck KGaA, lanxess, zachert
Merck KGaA’s chief financial officer Matthias Zachert is exiting the firm in order to fulfill a chief executive appointment at …
Servier signs cancer partnership
January 29, 2014Research and Development, Sales and Marketing AbbVie, Servier, breast cancer, curie
Servier has extended by three years its deal with leading research group Curie-Cancer to identify therapeutic targets for treating triple-negative …
Pfizer lung cancer drug suffers late-stage setback
January 28, 2014Research and Development, Sales and Marketing Cancer, NSCLC, Pfizer, Roche, Tarceva, dacomitinib
An experimental cancer drug developed by Pfizer has failed in two separate Phase III clinical studies. Dacomitinib is a tyrosine …
UCB launches online challenge to find new drugs
January 28, 2014Medical Communications UCB, crowdsourcing, innovation challenge, website
UCB has launched its ‘Innovation Challenge’ as it looks to pay members of the public to help develop new drugs. …
NICE looks at Xtandi again
January 28, 2014Sales and Marketing Astellas, NHS, NICE, Xtandi
NICE has announced it is to consult again on its decision to recommend Astellas Pharma’s prostate cancer drug Xtandi after …
Targacept appoints chairman
January 28, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Targacept, richard
Clinical-stage biopharma firm Targecept has appointed its non-executive director since 2002 John Richard to be its chairman of the board. …
NICE rejects ‘benefit’ test
January 28, 2014Sales and Marketing Dillon, EMIG, NHS, NICE, benefits
NICE has refused to include a ‘wider societal benefit’ test into its deliberations about which drugs should be available on …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
